Analysts Are Bullish on Top Healthcare Stocks: Matinas BioPharma (MTNB), Syndax Pharmaceuticals (SNDX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Matinas BioPharma (MTNB – Research Report) and Syndax Pharmaceuticals (SNDX – Research Report) with bullish sentiments.

Matinas BioPharma (MTNB)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Matinas BioPharma, with a price target of $3.00. The company’s shares closed last Friday at $0.75.

According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -40.3% and a 12.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics.

Currently, the analyst consensus on Matinas BioPharma is a Moderate Buy with an average price target of $3.00, implying a 302.7% upside from current levels. In a report issued on October 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.00 price target.

See today’s best-performing stocks on TipRanks >>

Syndax Pharmaceuticals (SNDX)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Syndax Pharmaceuticals, with a price target of $31.00. The company’s shares closed last Friday at $22.39.

According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -25.8% and a 22.3% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Aeglea Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Syndax Pharmaceuticals with a $32.67 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MTNB:

• Analysts Conflicted on These Industrial Goods Names: Pembina Pipeline (PBA), Boise Cascade (BCC) and Bloom Energy (BE)
• Analysts Offer Insights on Technology Companies: Microchip (MCHP), Paylocity (PCTY) and Nuvei Corp (NVEI)
• Lowe’s Sells Canadian Retail Business For $400 Million
• Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022
• Maxim Group Remains a Buy on Inmune Bio (INMB)